Search
Search Results
-
Circulating circular RNA hsa_circ_0023179 acts as a diagnostic biomarker for non-small-cell lung cancer detection
BackgroundLung cancer, the most prevalent cancer-related death worldwide, still lacks the means for early diagnosis. Because of the unique properties...
-
Prognostic Factors for Survival of Stage IB Non-small Cell Lung Cancer Patients: A 10-Year Follow-Up Retrospective Study
BackgroundThis study aimed to determine the prognostic factors for the long-term outcome of stage IB non-small cell lung cancer (NSCLC).
...
-
Effects of traditional Chinese medicine combined with chemotherapy for extensive-stage small-cell lung cancer patients on improving oncologic survival: study protocol of a multicenter, randomized, single-blind, placebo-controlled trial
BackgroundExtensive-stage small-cell lung cancer (ES-SCLC) is characterized by extensive metastases, aggressive progression, and poor prognosis....
-
The use of non-steroid anti-inflammatory drugs during radical resection correlated with the outcome in non-small cell lung cancer
AimsThe use of non-steroid anti-inflammatory drugs (NSAIDs) is conventional in management of postoperative pain in cancer patients, and further...
-
Intratumor heterogeneity is associated with less CD8+ T cell infiltration and worse survival in patients with small cell lung cancer
PurposeSmall cell lung cancer (SCLC) is a heterogeneous malignancy with genetic and phenotypic disparity. However, the association between intratumor...
-
Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skip** mutation, MET overexpression and amplification
PurposeMET exon 14 skip** is one of the rare mutations in non-small cell lung cancer (NSCLC), involving its pathogenesis and progression. The...
-
Concomitant Chest Wall Resection and Reconstruction in a Cohort of 254 Patients of Non-small Cell Lung Cancer Resections Between 2007 and 2019: a 12-Year Experience from a Single Center in Turkey
Lung cancer with chest wall invasion, which constitute 5ā10% of operable non-small cell lung cancer cases, is heterogeneous in terms of factors that...
-
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
BackgroundOsimertinib has become standard care for epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) patients...
-
NDR1 activates CD47 transcription by increasing protein stability and nuclear location of ASCL1 to enhance cancer stem cell properties and evasion of phagocytosis in small cell lung cancer
Small cell lung cancer (SCLC) is one of the most malignant types of lung cancer. Cancer stem cell (CSC) and tumor immune evasion are critical for the...
-
Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-Ī³ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients
BackgroundTuberculosis (TB), a highly contagious respiratory disease, presents a significant global health threat, with a notable increase in...
-
Predictive value of peripheral blood biomarkers in patients with non-small-cell lung cancer responding to anti-PD-1-based treatment
BackgroundThe introduction of the anti-PD-1 antibody has greatly improved the clinical outcomes of patients with non-small cell lung cancer (NSCLC)....
-
High pre-chemoradiotherapy pan-immune-inflammation value levels predict worse outcomes in patients with stage IIIB/C non-small-cell lung cancer
Background and objectivesWe explored the prognostic usefulness of the pan-immune-inflammation value (PIV) in patients with stage IIIB/C...
-
A nomogram to predict the cumulative risk for brain metastases in patients with limited-stage small cell lung cancer without prophylactic cranial irradiation
ObjectivePatients with small cell lung cancer (SCLC) have a high risk of develo** brain metastases (BM). Prophylactic cranial irradiation (PCI) is...
-
Comparison of Two-Port and Three-Port Approaches in Robotic Lobectomy for Non-Small Cell Lung Cancer
BackgroundRobot-assisted lobectomy has been used to treat non-small cell lung cancer and usually uses 3 or 4 ports and 3 or 4 robotic arms. We...
-
Endobronchial brachytherapy as definitive treatment for endobronchial metastasis after surgery of non-small cell lung cancer
BackgroundEndobronchial metastasis is a very rare type of recurrence after lung cancer surgery. Surgical intervention may be difficult to perform due...
-
Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors
With the continuous in-depth study of the interaction mechanism between viruses and hosts, the virus has become a promising tool in cancer treatment....
-
Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases
BackgroundAnlotinib, as a salvage treatment for patients after failure of third-line or later-line treatments for small cell lung cancer (SCLC), has...
-
First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
BackgroundIn the phase 3 CASPIAN study (NCT03043872), first-line durvalumab plus etoposide and cisplatin or carboplatin (EP) significantly improved...
-
A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-Small Cell Lung Cancer Patients
BackgroundMutations and deregulations in components of the Hedgehog (Hh) pathway have been associated with cancer onset and tumor growth in different...
-
CACA guidelines for holistic integrative management of lung cancer
Lung cancer (LC) is among the malignant tumors with the highest disease burden in the world, accounting for approximately 11.4% of all cancer cases,...